News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

NovoTTF-100A versus physician`s choice chemotherapy in recurrent glioblastom: a randomized phase 3 trial of a novel treatment modality. This is the report on the large trial that let to the FDA approval of the Novocure device


Posted on: 05/21/2012

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastom: a randomized phase 3 trial of a novel treatment modality. This is the report on the large trial that let to the FDA approval of the Novocure device
Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2016 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites